生血宁联合重组人促红细胞生成素治疗维持性血液透析患者肾性贫血临床研究

Clinical Study on Shengxuening Combined with Recombinant Human Erythropoietin for Renal Anemia in Patients with Maintenance Hemodialysis

目的:观察生血宁联合重组人促红细胞生成素(r HuEPO)治疗维持性血液透析(MHD)患者肾性贫血的疗效及对铁代谢指标的影响。方法:选择80例合并肾性贫血的MHD患者,随机分为观察组与对照组各40例。对照组口服琥珀酸亚铁及皮下注射rHuEPO治疗,观察组则口服生血宁片及皮下注射rHuEPO治疗。比较2组治疗前后血红蛋白(Hb)、红细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TAST)及超敏C-反应蛋白(hs-CRP)水平,并记录2组治疗前后rHuEPO用量。结果:与同组治疗前比较,2组治疗后血Hb、HCT水平及血清SF、TAST水平均升高(P<0.05),血清hs-CRP水平均降低(P<0.05),rHuEPO用量均减少(P<0.05);与对照组治疗后比较,观察组治疗后血Hb、HCT水平及血清SF、TAST水平均较高(P<0.05),血清hs-CRP水平较低(P<0.05),rHuEPO用量较少(P<0.05)。结论:生血宁联合r HuEPO治疗MHD合并肾性贫血,可有效提高患者的Hb水平,改善铁代谢指标。

Objective:To observe the curative effect of Shengxuening combined with recombinant human erythropoietin(rHuEPO) for renal anemia in patients with maintenance hemodialysis(MHD) and its effect on iron metabolism indexes.Methods:A total of 80 cases of MHD patients with renal anemia were randomly divided into the observation group and the control group, with 40 cases in each group. The control group was given the oral administration of ferrosi succinas and subcutaneous injection with rHuEPO,and the observation group was given the oral administration of Shengxuening tablets and subcutaneous injection with rHuEPO. Before and after treatment, the levels of hemoglobin(Hb), hematocrit(HCT),serum ferritin(SF), transferrin saturation(TAST) and hypersensitive C-reactive protein(hs-CRP) in the two groups were compared;the dosage of r HuEPO in the two groups was recorded. Results:After treatment,the levels of Hb and HCT in blood,serum SF and TAST were increased when compared with those before treatment(P<0.05),the levels of serum hsCRP were decreased(P<0.05),and the dosage of rHuEPO was decreased(P<0.05). After treatment,the levels of Hb and HCT in blood,serum SF and TAST in the observation group were higher than those in the control group(P<0.05),the level of serum hs-CRP was lower(P<0.05), and the dosage of rHuEPO was fewer(P<0.05). Conclusion: The therapy of Shengxuening combined with rHuEPO for renal anemia in patients with MHD can effectively increase their Hb levels and improve iron metabolism indexes.